

BERESKIN & PARR

BOX 401, 40 KING STREET WEST, TORONTO, ONTARIO M5H 3Y2  
PHONE (416) 364-7311 • FAX (416) 361-1398 • WWW.BERESKINPARR.COM

526 Rec'd 24 NOV 2000

24 NOV 2000

09/646,110

Please type a plus sign (+) inside this box →

Approved for use through 09/30/2000. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



## TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number

Filing Date

First Named Inventor

Group Art Unit

Examiner Name

Attorney Docket Number

### ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Response	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Additional Enclosure(s) (please identify below)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Small Entity Statement	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		
* - in addition to the 4 pages being submitted, 23 references are enclosed		

### SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Micheline Gravelle, Registration No. 40,261
Signature	
Date	November 22, 2000

### CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:

Typed or printed name

Signature

Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Barristers and Solicitors/Patent and Trade Mark Agents  
Practice Restricted to Intellectual Property Law

November 22, 2000



Micheline Gravelle B.Sc., M.Sc. (Immunol.)  
416 957 1682 mgravelle@bereskinparr.com

Our Reference: 10242-034

Commissioner for Patents and Trademarks  
Washington, D.C. 20231  
U.S.A.

Dear Sirs:

**Re: INFORMATION DISCLOSURE STATEMENT**

**United States Patent Application No. 09/646,110**

**Entitled: ALIPHATIC AMINO CARBOXYLIC AND AMINO PHOSPHONIC  
ACIDS, AMINO NITRILES AND AMINO TETRAZOLES AS  
CELLULAR RESCUE AGENTS**

**Filing Date: March 25, 1999**

**Inventors: Lilian E. Dyck et al.**

**Group Art Unit: Unknown as of Yet**

---

In accordance with 37 CFR 1.97 and 1.98, and in recognition of the duty of disclosure set forth in 37 CFR 1.56, Applicants hereby submit an Information Disclosure Statement on Form PTO-1449 containing a listing of patents and other publications which were cited on the Search Report of the corresponding PCT application. Applicants are also submitting the references listed on the Information Disclosure Statement.

The Examiner is requested to indicate consideration of these documents by initialling the appropriate column.

Applicants reserve the right to contest the applicability of any of these documents as prior art against the subject application.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits and therefore, no fee is required.

If the Examiner has any questions concerning this Information Disclosure Statement, he/she is requested to contact the undersigned. If it is determined that this Information Disclosure Statement has been filed under the wrong rule, the Patent and Trademark Office is requested to consider this Information Disclosure Statement under the proper rule (with a petition if necessary) and charge the appropriate fee to Deposit Account No. 02-2095.

Please charge any fees pursuant to 37 CFR 1.16 or 1.17 to Deposit Account No. 02-2095.

Respectfully submitted,

**Lilian E. Dyck et al.**



Micheline Gravelle  
Registration No. 40,261

Bereskin & Parr  
Box 401, 40 King Street West  
Toronto, Ontario, Canada  
M5H 3Y2

Tel. (416) 364-7311

Form PTO-1449 (REV. 2-32)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 10242-34		SERIAL NO. 09/646,110	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <small>(Use several sheets if necessary)</small>		APPLICANTS: Lilian E. Dyck et al.					
		INTERNATIONAL FILING DATE March 25, 1999			GROUP		
<b>U.S. PATENT DOCUMENTS</b>							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
		4,548,726	10/22/1985	Morris-Sherwood et al.			
		3,991,208	11/9/1976	Dudzinski et al.			
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLAS	TRANSLATION YES NO
		WO 97/45115	12/04/1997	WIPO			
		WO 92/15551	09/17/1992	WIPO			
		WO 96/05286	02/22/1996	WIPO			
		DE 41 00 856 A1	10/2/1991	Germany			X
		DE 11 39 738	11/15/1962	Germany			X
		DE 20 52 256	05/06/1971	Germany			X
		DE 24 42 239	03/13/1975	Germany			X
		DE 25 55 769	06/16/1977	Germany			X
		DE 15 67 221	04/16/1970	Germany			X
		FR 2 451 913	10/17/1980	France			X
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)							
	1.	Nishimura, Kuniko et al. "Inactivation of Monoamine Oxidase B by Analogues of the Anticonvulsant Agent Milacemide (2-(n-Pentylamino) acetamide)", Journal of Medicinal Chemistry, Vol. 36, No. 4, pp. 446-448, 1993.					
	2.	Satzinger, Gerhard. "5-Substituted and 1,5-condensed tetrazoles", Chemical Abstracts, Vol. 55, No. 15, p. 14441, 1961.					
	3.	Leonard, Frederick et al. "Potential Antiviral Agents", Journal of the American Chemical Society, Vol. 78, No. 6, pp. 1199-1201, 1956.					
	4.	Boit, Hans-G. "Beilsteins Handbuch Der Organischen Chemie, 4th Ed., 3rd Suppl., Vol. 4, Part 2, p. 1137, 1963.					
	5.	Luckenbach, Reiner. "Beilsteins Handbuch Der Organischen Chemie". 4th Ed., 4th Suppl., Vol. 4, Part. 3, p. 2386, 1980.					
	6.	Miyagishi, Shigeyoshi et al. "Phase Transition of N-Acyl Amino Acids with Different Acyl Group", Bulletin of the Chemical Society of Japan, Vol. 59, No. 2, pp. 557-562, 1986.					
	7.	Kirino, Osamu et al. "Studies on anti-fusarium disease activity of aminonitrile derivatives...", Chemical Abstracts, Vol. 92, No. 23, p. 167, 1980.					
EXAMINER:			DATE CONSIDERED:				
<b>*EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw Line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

